The combination of belinostat, an inhibitor of histone deacetylase, with decitabine increased the expression of epigenetically silenced MLH1 and MAGE-A1 and increased cisplatin sensitivity in ovarian cancer xenografts [136]. This evidence concerns the gene MLH1 and ovarian carcinoma.